What is Skyrizi?
Skyrizi (also known by its generic name risankizumab-rzaa) was approved by the FDA in April 2019 for the treatment of moderate-to-severe plaque psoriasis in adults. Skyrizi was approved by the FDA in January 2022 for the treatment of active psoriatic arthritis (PsA) in adults.
For both plaque psoriasis and PsA, Skyrizi is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterwards.
To learn more, please visit the Skyrizi website.
.png?ixlib=gatsbyFP&auto=compress%2Cformat&fit=max&rect=0%2C32%2C367%2C237&w=310&h=200)
SKYRIZI® (risankizumab-rzaa) is now available in the U.S. as a single dose injection for the treatment of adults with moderate-to-severe plaque psoriasis.
Read articleThe Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.
